Sageworth Trust Co lowered its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 34.9% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 22,693 shares of the company’s stock after selling 12,160 shares during the period. AbbVie comprises about 0.3% of Sageworth Trust Co’s portfolio, making the stock its 25th largest holding. Sageworth Trust Co’s holdings in AbbVie were worth $4,481,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently made changes to their positions in the company. Pine Haven Investment Counsel Inc grew its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Pine Haven Investment Counsel Inc now owns 18,102 shares of the company’s stock worth $3,575,000 after purchasing an additional 52 shares during the period. Frisch Financial Group Inc. increased its position in shares of AbbVie by 0.8% during the second quarter. Frisch Financial Group Inc. now owns 6,920 shares of the company’s stock worth $1,187,000 after acquiring an additional 53 shares during the period. First Citizens Financial Corp boosted its stake in shares of AbbVie by 0.9% in the 3rd quarter. First Citizens Financial Corp now owns 5,777 shares of the company’s stock valued at $1,141,000 after buying an additional 53 shares during the period. Sunflower Bank N.A. raised its holdings in shares of AbbVie by 0.4% in the 3rd quarter. Sunflower Bank N.A. now owns 13,723 shares of the company’s stock valued at $2,710,000 after purchasing an additional 53 shares in the last quarter. Finally, Professional Financial Advisors LLC boosted its position in shares of AbbVie by 3.4% during the 3rd quarter. Professional Financial Advisors LLC now owns 1,638 shares of the company’s stock worth $323,000 after acquiring an additional 54 shares in the last quarter. 70.23% of the stock is owned by institutional investors.
Insider Buying and Selling
In other AbbVie news, Chairman Richard A. Gonzalez sold 66,500 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the transaction, the chairman now owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.25% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Analysis on ABBV
AbbVie Stock Performance
Shares of ABBV traded down $1.80 during mid-day trading on Friday, reaching $187.85. 4,017,525 shares of the company’s stock traded hands, compared to its average volume of 5,287,914. The company has a debt-to-equity ratio of 8.51, a quick ratio of 0.71 and a current ratio of 0.81. The business’s 50-day moving average price is $194.14 and its 200-day moving average price is $178.16. The stock has a market capitalization of $331.72 billion, a P/E ratio of 55.73, a price-to-earnings-growth ratio of 2.66 and a beta of 0.63. AbbVie Inc. has a 12 month low of $135.85 and a 12 month high of $199.95.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Thursday, July 25th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.57 by $0.08. AbbVie had a return on equity of 203.66% and a net margin of 9.71%. The firm had revenue of $14.46 billion for the quarter, compared to analysts’ expectations of $14.02 billion. During the same period last year, the firm earned $2.91 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. Equities analysts predict that AbbVie Inc. will post 10.85 earnings per share for the current year.
AbbVie Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a dividend of $1.55 per share. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.30%. The ex-dividend date is Tuesday, October 15th. AbbVie’s dividend payout ratio is currently 183.98%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More
- Five stocks we like better than AbbVie
- Stock Sentiment Analysis: How it Works
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Canadian Penny Stocks: Can They Make You Rich?
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.